Medicine Recommendations

ADHD in children and adolescents aged 6 to 17 years for whom stimulants are not suitable, not tolerated or have been shown to be ineffective

Guselkumab for treating moderate to severe plaque psoriasis (NICE TA521)

For treating active psoriatic arthritis after inadequate response to DMARDs.

NICE TA711 - Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs

Treating active psoriatic arthritis after inadequate response to DMARDs - NICE TA815

NICE TA815 - Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs

Administration in patients with respiratory conditions

Care in the last weeks or days of life - Nausea and vomiting in the last days of life AND Agitation/terminal restlessness in the last days of life

Nausea and vomiting

Opioid-induced nausea and vomiting

Schizophrenia and other psychoses, mania, anxiety

Maintenance in schizophrenia and other psychoses

Rapid Tranquilisation

All licensed indications

Hidradenitis Suppurativa

Gender Dysphoria

Osteoarthritis

Psoriasis

Acute Gout (as per LSCMMG Guidelines)

For replacement therapy of adrenal insufficiency in children and adolescents (from birth to <18 years old)

Treatment of congenital adrenal hyperplasia (CAH) in adolescents aged 12 years and over and adults.

Treatment of adrenal insufficiency in adults.

Treatment of mild non-infectious allergic or inflammatory conjunctival diseases

Immediate release capsules 1.3mg, 2.6mg Modified release capsules 2mg, 4mg, 8mg, 16mg, 24mg Solution for injection for infusion 2mg/ml, 10mg/ml

Opioid rotation in patients with intolerable side effects or inadequate response to other opioids.